

# The <u>Alberta Coalition for PrevenTION</u> and Control of Vascular Disease (ACTION) Network

# Vascular Risk Reduction: Addressing Vascular Risk





## Vascular Risk Reduction (VRR)

#### Welcome!

- Presentation & Activities
- Focus: Managing known risk factors for vascular disease.
- Engage, collaborate and have fun!



## Vascular Risk Reduction

### Objectives:

- Discuss the impact of vascular disease in Canada.
- Identify non-modifiable, modifiable and manageable vascular risk factors.
- Describe appropriate management of known vascular risk factors.



## Impact of Vascular Disease

### Vascular Risk Round Up:

- Volunteer reads <u>Question</u> card.
- 2. The person with the correct <u>Answer</u> card must wave it and read the answer aloud.
- 3. If correct, it will be his/her turn to read out the question on the Question card.
- 4. If not correct, everyone must agree on the correct answer, then ask the person with the correct Answer card to read out his/her question.
- 5. Play continues until all questions have been read, along with their correct answers.



# **Addressing Vascular Risk Factors**















## Vascular Disease & Risk Factors

Most vascular disease(s) can be prevented or managed by addressing the risk factors

Why are risk factors such a big deal??

- Over 90% of Canadians have one or more risk factors
- Almost every person you come across can have increased risk for vascular disease









## Non-Modifiable Risk Factors

- Age
- Gender
- Family History/Genetics
- Ethnicity
- Previous Event (Heart Attack, Stroke, etc)



## What are some risk factors we can modify?





## **Modifiable Risk Factors**

May also be called "Healthy Lifestyle Behaviors"

- Tobacco Use
- Physical Inactivity
- Poor Diet
- Obesity or Overweight
- Excess Alcohol
- Unmanaged Stress
- Lack of Sleep






## "Manageable" Risk Factors

- Hypertension (High Blood Pressure)
- Dyslipidemia (High Cholesterol)
- "Metabolic Syndrome"
- Diabetes
- Cardiac Disease: Atrial Fibrillation











## **Hypertension (HTN)**


- #1 risk for Stroke and major risk for Heart Disease
  - #1 risk of death and disability
- Manage HTN, by addressing modifiable risk factors (healthy lifestyle behaviours)
- Antihypertensive therapy should be strongly considered if blood pressure is not within target



**Services** 



# **Hypertension Targets**





# **Exogenous** Factors That Can Elevate Blood Pressure

- Prescription Drugs:
  - NSAIDS, including Cox II inhibitors
  - Corticosteroids and anabolic steroids
  - Oral contraceptives and other hormonal therapy
  - Vasoconstricting/sympathominetic decongestants
  - Calcineurin inhibitors (cyclosporins, tacrolimus)
  - Erythropoietin and analogues
  - MAOI's Monoamine Oxidase Inhibitors (Marplan, Nardil, Parnate)
  - Midodrine



# **Exogenous** Factors That Can Elevate Blood Pressure

#### Others

Licorice Root

Stimulants including cocaine

Sodium

**Excessive Alcohol** 

Sleep Apnea



# Recommended Health Behaviours in Adults with Hypertension:



Intervention	Target		
Reduce foods with added sodium	→ 2000 mg /day		
Weight loss	BMI <25 kg/m <sup>2</sup>		
Alcohol restriction	≤ 2 drinks/day		
Physical activity	30-60 minutes 4-7 days/week		
Dietary patterns	DASH diet		
Smoking cessation	Smoke free environment		
Waist circumference	Men <102 cm Women <88 cm		







# Impact of Health Behaviours on Blood Pressure

Intervention	Systolic BP (mmHg)	<b>Diastolic BP</b> (mmHg)
Diet and weight control	-6.0	-4.8
Reduced salt/sodium intake	- 5.4	- 2.8
Reduced alcohol intake (heavy drinkers)	-3.4	-3.4
DASH diet	-11.4	-5.5
Physical activity	-3.1	-1.8
Relaxation therapies	-3.7	-3.5
Multiple interventions	-5.5	-4.5







# The treatment of hypertension is all about vascular protection

Statins are recommended in high risk hypertensive patients based on having established atherosclerotic disease or at least 3 of the following:

- Male gender
- 55 y or older
- Smoking
- Type 2 Diabetes
- Total-C/HDL-C ratio of 6 or higher
- Premature Family History of CV disease

- Previous Stroke or TIA
- LVH
- ECG abnormalities
- Microalbuminuria or Proteinuria
- Peripheral Vascular Disease

ASCOT-LLA Lancet 2003;361:1149-58







## **Medication Recommendations**

- Low doses of multiple drugs may be more effective and better tolerated than higher doses of fewer drugs.
- A combination of two first line drugs may also be considered as initial treatment if SBP 20 mmHg above target or is DBP is 10 mmHg above target.



# Treatment of Systolic-Diastolic Hypertension without Other Compelling Indications


#### TARGET <140/90 mmHg Lifestyle modification A combination of 2 first line drugs may be considered as initial therapy if the blood pressure is >20 mmHg systolic **Initial therapy** or >10 mmHg diastolic above target Long-acting **Thiazide** Beta-**ACEI ARB CCB** diuretic blocker\* **CONSIDER Dual Combination** Nonadherence Secondary HTN Interfering drugs or \*Not indicated as first lifestyle **Triple or Quadruple** line therapy over 60 y White coat effect **Therapy**







# HTN Treatment with Co-morbidities





## Vascular Protection for Hypertensive Patients: ASA

Low Dose ASA in patients ≥ 50 years

Caution should be exercised if BP is not controlled.



### \*\*\* Reminder \*\*\*

 ACE and ARB combinations are not recommended except for HTN with heart failure refractory to an ACE alone.



# How do I monitor and follow up?

- Recommend regular home BP monitoring and keeping a log
- Ask about potential symptoms (dizziness)
- Encourage lifestyle modification at every visit
- Additional blood tests may include serum creatinine, potassium, HbA1C in patients with diabetes




## **Dyslipidemia**

- High cholesterol can contribute to atherosclerosis
- Treatment targets are based on the level of risk
  - Known Vascular Disease or High cardiovascular risk (FRS > 20%)
     Lifestyle modification + Statin therapy
- For those not already treated and FRS 10-19%, Statin therapy will reduce risk



#### Canadian Cardiovascular Society

# Dyslipidemia Treatment Recommendations





# Statins: "Myth Busting" for Patients

- 1. My cholesterol is normal, why do I need a statin?
- 2. Does changing my diet work as well as taking a statin?
- 3. What kind of side effects do statins have?
- 4. Is it true that statins cause serious muscle problems?
- 5. Is it true that statins can damage the liver?
- 6. Do I have to take a statin for the rest of my life?
- 7. Are natural health products a good option to statins?
- 8. If taking a statin, Do I have to take coenzyme Q10?
- 9. When is the best time of day to take a statin?
- 10. Is Lipitor more harmful compared to other statins?



# Statins: "Myth Busting" for HCPs

- 1. Should statins be used in elderly patients?
- 2. If CK is elevated, should the statin be stopped?
- 3. If myalgias without CK elevation, should statin be stopped?
- 4. If not at LDL-C target with a statin, is adding a fibrate OK?
- 5. Does high-dose statin therapy increase risk of myopathy?
- 6. Do statins cause diabetes?
- 7. Do statins cause cognitive impairment?
- 8. Do statins cause cancer?
- 9. Does the dose of statin matter in primary prevention?



## Metabolic Syndrome (aka Syndrome X)

May be diagnosed if ≥ 3 of the following conditions:

❖ Fasting Glucose >5.6 mmol/L

❖ Blood Pressure >130/85 mmHg

❖ Triglycerides >1.7 mmol/L

♦ HDL <1.0 mmol/L in men</p>

<1.3 mmol/L in women

Abdominal Obesity (Caucasians)

Waist Circumference >102 cm in men

>88 cm in women



## Metabolic Syndrome – Cont'd

The good news... even modest improvements can improve health and reduce poor health outcomes

#### Research has shown:

↓ body weight 5-7% and ↑ physical activity to 150 mins/wk could reduce the risk of developing Type 2 DM in obese patients

Management includes targeting modifiable risk factors (diet, activity, weight) <u>and</u> monitoring blood glucose, cholesterol and blood pressure regularly



# **Diabetes - Assessing Plasma Glucose**

Test Result	FPG (mmol/l)	OGTT (mmol/l)	HbA1C (%)
Normal	FPG ≤ 6	OGTT < 7.8	HbA1c < 6
Impaired	6.1 ≤ FPG < 7	7.8 ≤ OGTT < 11.1	6 ≤ HbA1c ≤ 6.4
Diabetes	FPG≥7	OGTT ≥ 11.1	HbA1c ≥ 6.5

<sup>\*</sup>If one of these measurements was indicating diabetes without any hyperglycemia symptoms, the test should be repeated on another day to confirm the diagnosis



## **Glycemic Control Targets**

Glycemic control targets should be <u>individualized</u> based on the following:

- Age
- Diabetes duration
- Life expectancy
- Risk of severe hypoglycemia
- Presence or absence of cardiovascular disease

A target of HbA1c ≤ 7% is recommend in most patients with diabetes



## **Diabetes Management**

Optimal glucose control is very important in diabetes treatment. Diabetes can be treated by:

- 1. Lifestyle Adjustments
- 2. Oral Antihyperglycemic medications
- 3. Insulin

Type 2 diabetes treatment should start with lifestyle adjustment; if lifestyle adjustment fails to achieve the target blood glucose after 2-3 months, antihyperglycemic medication should be started



## **Diabetes – Medical Management**

Diabetes treatment should be individualized based on the properties of the antihyperglycemic medications, e.g. efficacy, contraindications, side effects and risk of hypoglycemia

For more information on specific pharmacotherapy recommendations, go to the Canadian Diabetes Association 2013 Clinical Practice Guidelines at:

http://guidelines.diabetes.ca/





## **Atrial Fibrillation**



Irregular rhythm / contraction of the atrium muscles

Why is it important to treat?

- Formation of blood clots ———— Stroke / TIA
- Worsening of other cardiac conditions (i.e. heart failure)

When is it important to treat?


- Decision tools (CHADS2 or CHA2DS2-VASc)
- CCS Algorithm





## **Atrial Fibrillation: Treatment**


#### The "CCS Algorithm" for OAC Therapy in AF



Canadian Journal of Cardiology 2014 30, 1114-1130DOI: (10.1016/j.cjca.2014.08.001)




## **Atrial Fibrillation: Treatment (in the ED)**



Canadian Journal of Cardiology 2014 30, 1114-1130DOI: (10.1016/j.cjca.2014.08.001)



## **Atrial Fibrillation: Treatment**



Canadian Journal of Cardiology 2014 30, 1114-1130DOI: (10.1016/j.cjca.2014.08.001)



## **Atrial Fibrillation: Treatment**

### Anti-coagulants

- NOACs (novel oral anticoagulant)
  - include Dabigatran (Pradex), Rivaroxaban (Xarelto) & Apixaban (Eliquis)
- Warfarin (Coumadin)

### Rhythm and Rate control

Beta-blockers, CCB's (Digoxin), Amiodarone

\*Individuals with atrial fibrillation have a risk of stroke that is 3 to 5 times greater than those without AF.



## Addressing Vascular Risk

### Key Messages:

- Support Healthy Lifestyle Behaviours to reduce vascular risk
- Strongly consider antihypertensive therapy if blood pressure is not within target
- Base dyslipidemia treatment on level of vascular risk
  - Those with <u>High Cardiovascular Risk</u> or known <u>Vascular Disease</u> should be treated with <u>statin therapy</u>
- Optimal glucose control is important in diabetes treatment.
- Treat atrial fibrillation when indicated



## **Questions?**





## A Special Thanks to:

The Calgary & Lethbridge Vascular Risk Reduction Programs and the CvHS SCN - VRR RxEACH Project, for their support and collaboration.





## **References:**

Canadian Cardiovascular Society:

http://www.ccs.ca/index.php/en/

C-CHANGE Clinical Resource Centre:

http://www.c-changecrc.ca/

Harmonization of guidelines for the prevention and treatment of cardiovascular disease: the C-CHANGE Initiative – <a href="www.cmaj.ca">www.cmaj.ca</a> (November 18, 2014)

Heart and Stroke Foundation of Canada:

http://heartandstroke.com



### References:

Hypertension Canada (CHEP recommendations):

http://hypertension.ca

Vascular Risk Reduction Resource:

http://www.albertahealthservices.ca/10585.asp